Vasopressin, unlike phorbol ester, fails to synergistically interact with pituitary adenylate cyclase activating polypeptide (PACAP) in stimulating cyclic AMP formation and ACTH secretion in cultured anterior pituitary cells

Pituitary adenylate cyclase-activating polypeptide (PACAP) in fetal cord blood

BACKGROUND

Pituitary adenylate cyclase-activating peptide (PACAP) is a centrally-acting peptide with highest concentration within the limbic area of the brain. PACAP is also expressed in and affects the functions of vascular and nervous tissues, endocrine glands, and the placenta. PACAP appears to be associated with the 'fight-or-flight' response to emergency partly through its effect on adrenal production of cortisol and catecholamines.

OBJECTIVES

We sought to explore the impact of labor as a stressor on the level of PACAP in the fetus, and hypothesized that PACAP levels would be increased when labor, abnormal fetal heart tracing, or fetal growth impairment was evident.

METHODS

Fetal cord venous blood samples were collected immediately after delivery from a random group of women undergoing either vaginal or Cesarean delivery. The blood was placed in chilled EDTA-aprotinin containing tubes, centrifuged, and stored at -80°C for PACAP immunoassay. Delivery data were abstracted for analysis.

RESULTS

The level of PACAP in cord blood was similar in both males and females. There was a trend toward higher levels in the cord blood of fetuses delivered by Cesarean compared to those delivered vaginally. PACAP levels were unrelated to birth weight, Apgar scores, and the presence or absence of labor prior to delivery.

CONCLUSIONS

While PACAP and its receptor are expressed in placenta, and PACAP protein is found in cord blood, no effect of labor stress on PACAP was found. Further research is needed to understand the role of PACAP in gestation and parturition.

Inhibition of gastric acid secretion in rat stomach by PACAP is mediated by secretin, somatostatin, and PGE(2)

Pituitary adenylate cyclase-activating polypeptide (PACAP), existing in two variants, PACAP-27 and PACAP-38, is found in the enteric nervous system and regulates function of the digestive system. However, the regulatory mechanism of PACAP on gastric acid secretion has not been well elucidated. We investigated the inhibitory action of PACAP-27 on acid secretion and its mechanism in isolated vascularly perfused rat stomach. PACAP-27 in four graded doses (5, 10, 20, and 50 microg/h) was vascularly infused to determine its effect on basal and pentagastrin (50 ng/h)-stimulated acid secretion. To study the inhibitory mechanism of PACAP-27 on acid secretion, a rabbit antisecretin serum, antisomatostatin serum, or indomethacin was administered. Concentrations of secretin, somatostatin, PGE(2), and histamine in portal venous effluent were measured by RIA. PACAP-27 dose-dependently inhibited both basal and pentagastrin-stimulated acid secretion. PACAP-27 at 10 microg/h significantly increased concentrations of secretin, somatostatin, and PGE(2) in basal or pentagastrin-stimulated state. The inhibitory effect of PACAP-27 on pentagastrin-stimulated acid secretion was reversed 33% by an antisecretin serum, 80.0% by an antisomatostatin serum, and 46.1% by indomethacin. The antisecretin serum partially reduced PACAP-27-induced local release of somatostatin and PGE(2). PACAP-27 at 10 microg/h elevated histamine level in portal venous effluent, which was further increased by antisomatostatin serum. However, antisomatostatin serum did not significantly increase acid secretion. It is concluded that PACAP-27 inhibits both basal and pentagastrin-stimulated gastric acid secretion. The effect of PACAP-27 is mediated by local release of secretin, somatostatin, and PGE(2) in isolated perfused rat stomach. The increase in somatostatin and PGE(2) levels in portal venous effluent is, in part, attributable to local action of the endogenous secretin.

Co-expression of a Ca2+-inhibitable adenylyl cyclase and of a Ca2+-sensing receptor in the cortical thick ascending limb cell of the rat kidney. Inhibition of hormone-dependent cAMP accumulation by extracellular Ca2+

The Ca2+-sensing receptor protein and the Ca2+-inhibitable type 6 adenylyl cyclase mRNA are present in a defined segment of the rat renal tubule leading to the hypothesis of their possible functional co-expression in a same cell and thus to a possible inhibition of cAMP content by extracellular Ca2+. By using microdissected segments, we compared the properties of regulation of extracellular Ca2+-mediated activation of Ca2+ receptor to those elicited by prostaglandin E2 and angiotensin II. The three agents inhibited a common pool of hormone-stimulated cAMP content by different mechanisms as follows. (i) Extracellular Ca2+, coupled to phospholipase C activation via a pertussis toxin-insensitive G protein, induced a dose-dependent inhibition of cAMP content (1.25 mM Ca2+ eliciting 50% inhibition) resulting from both stimulation of cAMP hydrolysis and inhibition of cAMP synthesis; this latter effect was mediated by capacitive Ca2+ influx as well as release of intracellular Ca2+. (ii) Angiotensin II, coupled to the same transduction pathway, also decreased cAMP content; however, its inhibitory effect on cAMP was mainly accounted for by an increase of cAMP hydrolysis, although angiotensin II and extracellular Ca2+ can induce comparable release of intracellular Ca2+. (iii) Prostaglandin E2, coupled to pertussis toxin-sensitive G protein, inhibited the same pool of adenylyl cyclase units as extracellular Ca2+ but by a different mechanism. The functional properties of the adenylyl cyclase were similar to those described for type 6. The results establish that the co-expression of a Ca2+-inhibitable adenylyl cyclase and of a Ca2+-sensing receptor in a same cell allows an inhibition of cAMP accumulation by physiological concentrations of extracellular Ca2+.

Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis

Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are members of a family of regulatory peptides that are widely distributed in the body and share numerous biologic actions. The two peptides display a remarkable amino acid-sequence homology, and bind to a class of G protein-coupled receptors, named PACAP/VIP receptors (PVRs), whose signaling mechanism mainly involves the activation of adenylate-cyclase and phospholipase-C cascades. A large body of evidence suggests that VIP and PACAP play a role in the control of the hypothalamo--pituitary-adrenal (HPA) axis, almost exclusively acting in a paracrine manner, since their blood concentration is very low. VIP and PACAP are contained in both nerve fibers and neurons of the hypothalamus, and VIP, but not PACAP, is also synthesized in the pituitary gland. Both peptides are expressed in the adrenal gland, and especially in medullary chromaffin cells. All the components of the HPA axis are provided with PVRs. VIP and PACAP enhance pituitary ACTH secretion, VIP by eliciting the hypothalamic release of CRH and potentiating its secretagogue action, and PACAP by directly stimulating pituitary corticotropes. Through this central mechanism, VIP and PACAP may increase mineralo- and glucocorticoid secretion of the adrenal cortex. VIP but not PACAP also exerts a weak direct secretagogue action on adrenocortical cells by activating both PVRs and probably a subtype of ACTH receptors. VIP and PACAP raise aldosterone production via a paracrine indirect mechanism involving the stimulation of medullary chromaffin cells to release catecholamines, which in turn enhance the secretion of zona glomerulosa cells via a beta-adrenoceptor-mediated mechanism. PACAP appears to be able to evoke a glucocorticoid response through the activation, at least in the rat, of the intramedullary CRH/ACTH system. The relevance of these effects of VIP and PACAP under basal conditions is questionable, although there are indications that endogenous VIP is involved in the maintenance of the normal growth and steroidogenic capacity of rat adrenal cortex. However, indirect evidence suggests that these peptides might play a relevant role under paraphysiological conditions (e.g., in the mediation of HPA axis responses to cold and inflammatory stresses) or may be somehow involved in the pathogenesis of Cushing disease or some case of hyperaldosteronism associated with secreting pheochromocytomas.

Regulation of adrenocorticotropin secretion in vitro by anterior pituitary corticotrophs from fallow deer (Dama dama)

The actions of corticotropin-releasing hormone (CRH), vasopressin (VP), the synthetic glucocorticoid dexamethasone (DEX), and mifepristone (RU 486), a glucocorticoid antagonist, on the secretion of adrenocorticotropin (ACTH) by cultured fallow deer corticotrophs were studied in vitro. On Day 5 of primary culture, corticotrophs were challenged for up to 4 hr with medium alone (Control), CRH, VP, DEX, forskolin (FSK), phorbol ester (TPA), cyclic AMP (cAMP), and/or RU 486 at various concentrations and combinations. CRH, VP, FSK and TPA each stimulated (P < 0.01) the secretion of ACTH in dose- and time-related manners. Relative to Control, CRH at 0.001 and 0.1 microM and VP at 0.01 and 1 microM increased (P < 0.01) medium concentration of ACTH by 7.3-, 13.5-, 3.7- and 9.0-fold, respectively. There was a treatment x incubation time interaction (P < 0.01) such that at 30-min posttreatment, CRH-induced ACTH secretion tended (P < 0.10) to be less than that obtained via VP treatment, whereas at 1, 3, and 4 hr posttreatment, medium concentration of ACTH from cells treated with 0.1 microM CRH was greater (P < 0.05) than that in cells treated with 1 microM VP. At equimolar doses of 0.01 and 0.1 microM, CRH was 3.4- and 3.0-fold more potent (treatment x dose, P < 0.05) than VP. Cotreatment with 1 microM DEX reduced (P < 0.001) the stimulatory effects of CRH (0.1 microM), VP (1 microM), FSK (10 microMs), TPA (0.1 microM), and cAMP (0.001 M). However, the coaddition of RU 486 (1 microM) to the CRH plus DEX- and the FSK plus DEX-treated wells partially negated the inhibitory effects of DEX. RU 486 completely negated the inhibitory effects of DEX on the VP-, TPA-, and cAMP-stimulated secretion of ACTH. These data indicate that CRH is a more potent stimulator of ACTH secretion than is VP in primary culture of fallow deer pituitary cells. This study also demonstrates the utility of an in vitro culture system to investigate stress-related hormonal interactions in cervids.

Inhibition of protein phosphatases by okadaic acid and calyculin-A differentially modulates hormonal- and forskolin-stimulated formation of cyclic AMP in AtT-20 corticotrophs: effect of pituitary adenylate activating polypeptide and corticotropin-releasing factor

The effect of phosphatase inhibitors okadaic acid and calyculin-A on cAMP formation and adrenocorticotropic hormone (ACTH) secretion in AtT-20 corticotrophs was investigated. Both okadaic acid and calyculin-A inhibited dose-dependently the accumulation of cAMP in cells stimulated with pituitary adenylate cyclase activating factor (PACAP) and corticotropin-relating hormone (CRF). While in the case of okadaic acid the half-maximum inhibiting concentration was similar for both peptides (IC50 = 4 x 10(-7) M), it appeared that calyculin-A was about one order of magnitude more efficient in inhibiting the effect of PACAP than that of CRF (IC50 = 3.8 x 10(-9) M vs 2.0 x 10(-8) M, respectively). Importantly, the inhibitors blocked the activation by cholera toxin (which acts on Gs-like proteins) of cAMP formation, but failed to alter the effect of forskolin (which bypasses the receptor-G protein complex and activates adenylyl cyclase directly). Treatment of cells with calyculin-A significantly dampened adenylyl cyclase activity in cell membrane fraction, though to a lesser extent than it blocked cAMP formation in the whole cell. Both okadaic acid and calyculin-A inhibited CRF- and PACAP-induced secretion of ACTH. Our data hint that in AtT-20 corticotrophs, inhibition of phosphatases by modulating the state of phosphorylation of the receptor-G proteins complexes for CRF and PACAP, regulates cAMP formation and ACTH secretion.